We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

66 hedge funds and large institutions have $27.4M invested in Matinas BioPharma in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% more ownership

Funds ownership: 0.24% → 0.25% (+0.01%)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

1% less funds holding

Funds holding: 67 → 66 (-1)

18% less capital invested

Capital invested by funds: $33.5M → $27.4M (-$6.11M)

Holders
66
Holders Change
-1
Holders Change %
-1.49%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
12
Reduced
13
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.68M
2
SIG
Sargent Investment Group
Maryland
+$410K
3
CCM
Courage Capital Management
Tennessee
+$214K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$205K
5
SWM
Spire Wealth Management
Virginia
+$169K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$967K
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$221K
3
Jane Street
Jane Street
New York
-$211K
4
VF
Virtu Financial
New York
-$156K
5
PAG
Private Advisor Group
New Jersey
-$75.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$8.01M +$55K +1,028 +0.7%
BlackRock
2
BlackRock
New York
$4.34M +$1.68M +31,432 +58%
SIG
3
Sargent Investment Group
Maryland
$3.67M +$410K +7,678 +12%
CCM
4
Courage Capital Management
Tennessee
$1.92M +$214K +4,000 +12%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.6M +$205K +3,842 +14%
AWA
6
Arkadios Wealth Advisors
Georgia
$1.41M – – –
JEST
7
JTC Employer Solutions Trustee
Jersey
$779K – – –
BCM
8
Bridgeway Capital Management
Texas
$761K -$32.1K -600 -4%
State Street
9
State Street
Massachusetts
$666K – – –
SCA
10
STALEY CAPITAL ADVISERS
Pennsylvania
$606K – – –
MSFS
11
Main Street Financial Solutions
Pennsylvania
$405K – – –
Northern Trust
12
Northern Trust
Illinois
$334K – – –
LPL Financial
13
LPL Financial
California
$280K – – –
Truist Financial
14
Truist Financial
North Carolina
$207K – – –
Bank of New York Mellon
15
Bank of New York Mellon
New York
$171K – – –
PTP
16
Platform Technology Partners
New York
$163K -$4.28K -80 -2%
SWM
17
Spire Wealth Management
Virginia
$163K +$169K +3,163 +5,272%
DA
18
DCF Advisers
Connecticut
$156K – – –
PAG
19
Private Advisor Group
New Jersey
$151K -$75.9K -1,420 -32%
Bank of America
20
Bank of America
North Carolina
$148K +$155K +2,891 +8,031%
Citadel Advisors
21
Citadel Advisors
Florida
$119K -$71.4K -1,336 -36%
RWA
22
Ropes Wealth Advisors
Massachusetts
$101K – – –
VF
23
Virtu Financial
New York
$86K -$156K -2,923 -63%
CDH
24
Charles D. Hyman
$81K – – –
Charles Schwab
25
Charles Schwab
California
$80K – – –
1
2 3 4

MTNB Hedge Fund Activity: Q4 2021 in Review

66 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2021, worth a combined $27.4M — down 18% from $33.5M a quarter earlier.

Fund positioning in MTNB was balanced in Q4 2021: 11 funds opened new positions, 11 closed out, 12 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $1.68M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $967K sold.

  • 66 institutional investors held Matinas BioPharma (MTNB) as of Q4 2021, down from 67 in Q3 2021.
  • Funds reported $27.4M of Matinas BioPharma stock for Q4 2021, down 18% quarter-over-quarter.
  • 11 funds opened new Matinas BioPharma positions in Q4 2021 and 11 closed out, a net change of 0 holders.
  • The largest Matinas BioPharma buyer in Q4 2021 was BlackRock, an estimated $1.68M added.
  • The largest Matinas BioPharma seller in Q4 2021 was GSA Capital Partners, an estimated $967K sold.

Based on aggregated 13F filings for Q4 2021.